Rapport Therapeutics (RAPP) Cash from Financing Activities (2023 - 2026)
Rapport Therapeutics (RAPP) posted quarterly Cash from Financing Activities of $531000.0 for Q1 2026, up 10520.0% year-over-year from N/an in Q1 2025, and up 70.74% quarter-over-quarter from $311000.0 in Q4 2025.
Rapport Therapeutics (RAPP) Cash from Financing Activities (2023 - 2026) Analysis & Trends
Rapport Therapeutics (RAPP) has reported Cash from Financing Activities for 4 consecutive years, with $531000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Financing Activities rose 10520.0% year-over-year to $531000.0; the TTM figure through Mar 2026 stood at $271.3 million (up 71.75% YoY), while the FY2025 annual figure was $270.8 million, up 22.18% from the prior year.
- Cash from Financing Activities grew to $531000.0 in Q1 2026 per RAPP's latest filing, from $311000.0 in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $270.5 million in Q3 2025 and bottomed at -$1.4 million in Q3 2024.
- Historically, Cash from Financing Activities has averaged $52.6 million across 4 years, with a median of $311000.0 in 2025.
- Annual changes were most pronounced in 2024 — Cash from Financing Activities plunged 101.63% — and 2025, when it surged 19506.96%.
- Rapport Therapeutics' Cash from Financing Activities stood at -$140000.0 in 2023, then jumped by 105.0% to $7000.0 in 2024, then surged by 4342.86% to $311000.0 in 2025, then soared by 70.74% to $531000.0 in 2026.
- Business Quant data shows RAPP's Cash from Financing Activities at $531000.0 in Q1 2026, $311000.0 in Q4 2025, and $270.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.42 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -6.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -207,909.22 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -273.15 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 36.24 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 27.18 Mn |
| 10 | Rapport Therapeutics | 2.27 Bn | 2.27 Bn | - | 1.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.41 Mn |
| Jun 30, 2026 | 1.41 Mn |
| Mar 31, 2026 | 531,000.00 |
| Mar 31, 2026 | 531,000.00 |
| Dec 31, 2025 | 311,000.00 |
| Dec 31, 2025 | 311,000.00 |
| Sep 30, 2025 | 270.53 Mn |
| Sep 30, 2025 | 270.53 Mn |
| Jun 30, 2025 | -63,000.00 |
| Jun 30, 2025 | -63,000.00 |
| Mar 31, 2025 | 5,000.00 |
| Mar 31, 2025 | 5,000.00 |
| Dec 31, 2024 | 7,000.00 |
| Dec 31, 2024 | 7,000.00 |
| Sep 30, 2024 | -1.39 Mn |
| Sep 30, 2024 | -1.39 Mn |
| Jun 30, 2024 | 159.35 Mn |
| Jun 30, 2024 | 159.35 Mn |
| Mar 31, 2024 | 63.66 Mn |
| Mar 31, 2024 | 63.66 Mn |